Catalent Inc
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies;… Read more
Catalent Inc (CTLT) - Net Assets
Latest net assets as of September 2024: $3.54 Billion USD
Based on the latest financial reports, Catalent Inc (CTLT) has net assets worth $3.54 Billion USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.71 Billion) and total liabilities ($6.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.54 Billion |
| % of Total Assets | 36.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | 24.33% |
| 10-Year Change | 468.45% |
| Growth Volatility | 29.14 |
Catalent Inc - Net Assets Trend (2012–2024)
This chart illustrates how Catalent Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Catalent Inc (2012–2024)
The table below shows the annual net assets of Catalent Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $3.60 Billion | -22.24% |
| 2023-06-30 | $4.63 Billion | -3.34% |
| 2022-06-30 | $4.79 Billion | +22.48% |
| 2021-06-30 | $3.92 Billion | +35.06% |
| 2020-06-30 | $2.90 Billion | +72.38% |
| 2019-06-30 | $1.68 Billion | +54.74% |
| 2018-06-30 | $1.09 Billion | +50.20% |
| 2017-06-30 | $723.50 Million | +13.78% |
| 2016-06-30 | $635.90 Million | +0.30% |
| 2015-06-30 | $634.00 Million | +270.52% |
| 2014-06-30 | $-371.80 Million | +9.38% |
| 2013-06-30 | $-410.30 Million | -16.99% |
| 2012-06-30 | $-350.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Catalent Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 60110000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00 Million | 0.06% |
| Other Comprehensive Income | $-404.00 Million | -11.21% |
| Other Components | $4.79 Billion | 132.82% |
| Total Equity | $3.60 Billion | 100.00% |
Catalent Inc Competitors by Market Cap
The table below lists competitors of Catalent Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dynatrace Holdings LLC
NYSE:DT
|
$11.46 Billion |
|
SITC International Holdings Company Limited
PINK:SITIY
|
$11.47 Billion |
|
FISHER + PAYKEL HEALTH.
F:FPLB
|
$11.49 Billion |
|
Synnex Corporation
NYSE:SNX
|
$11.51 Billion |
|
Kerry Group
IR:KRZ
|
$11.45 Billion |
|
Asian Paints Limited
NSE:ASIANPAINT
|
$11.44 Billion |
|
Will Semiconductor Co Ltd
SHG:603501
|
$11.43 Billion |
|
Evergreen Marine Corp Taiwan Ltd
TW:2603
|
$11.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Catalent Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,635,000,000 to 3,604,000,000, a change of -1,031,000,000 (-22.2%).
- Net loss of 1,043,000,000 reduced equity.
- Other comprehensive income decreased equity by 50,000,000.
- Other factors increased equity by 62,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.04 Billion | -28.94% |
| Other Comprehensive Income | $-50.00 Million | -1.39% |
| Other Changes | $62.00 Million | +1.72% |
| Total Change | $- | -22.24% |
Book Value vs Market Value Analysis
This analysis compares Catalent Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-06-30 | $-2.99 | $63.48 | x |
| 2013-06-30 | $-3.50 | $63.48 | x |
| 2014-06-30 | $-3.17 | $63.48 | x |
| 2015-06-30 | $5.23 | $63.48 | x |
| 2016-06-30 | $5.05 | $63.48 | x |
| 2017-06-30 | $5.71 | $63.48 | x |
| 2018-06-30 | $8.16 | $63.48 | x |
| 2019-06-30 | $11.52 | $63.48 | x |
| 2020-06-30 | $19.03 | $63.48 | x |
| 2021-06-30 | $23.03 | $63.48 | x |
| 2022-06-30 | $26.94 | $63.48 | x |
| 2023-06-30 | $25.61 | $63.48 | x |
| 2024-06-30 | $19.91 | $63.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Catalent Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23.81%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 2.71x
- Recent ROE (-28.94%) is below the historical average (6.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -1.44% | 0.54x | 0.00x | $10.67 Million |
| 2013 | 0.00% | -2.59% | 0.59x | 0.00x | $-5.63 Million |
| 2014 | 0.00% | 0.89% | 0.59x | 0.00x | $53.38 Million |
| 2015 | 33.47% | 11.59% | 0.58x | 4.96x | $148.80 Million |
| 2016 | 17.53% | 6.03% | 0.60x | 4.86x | $47.91 Million |
| 2017 | 15.18% | 5.29% | 0.60x | 4.77x | $37.45 Million |
| 2018 | 7.69% | 3.39% | 0.54x | 4.17x | $-25.07 Million |
| 2019 | 8.17% | 5.46% | 0.41x | 3.68x | $-30.76 Million |
| 2020 | 5.97% | 5.59% | 0.40x | 2.68x | $-116.88 Million |
| 2021 | 14.94% | 14.63% | 0.44x | 2.33x | $193.50 Million |
| 2022 | 10.41% | 10.34% | 0.46x | 2.19x | $19.50 Million |
| 2023 | -5.01% | -5.43% | 0.40x | 2.33x | $-695.50 Million |
| 2024 | -28.94% | -23.81% | 0.45x | 2.71x | $-1.40 Billion |
Industry Comparison
This section compares Catalent Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Catalent Inc (CTLT) | $3.54 Billion | 0.00% | 1.74x | $11.45 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |